Melanoma Research Alliance Hails FDA’s First ‘Triplet’ Combination Approval for Melanoma

Source: businesswire, August 2020

The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research worldwide, welcomes the decision by the U.S. Food and Drug Administration (FDA) approving Genentech’s Tecentriq ® (atezolizumab) plus Cotellic ® (cobimetinib) and Zelboraf ® (vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma patients.

The newly approved triplet treatment is the first FDA-approved combination for metastatic melanoma that brings together immunotherapy with targeted therapies. Tecentriq, an immunotherapy, works by releasing the brakes on the immune system allowing it to attack cancerous cells. Cotellic and Zelboraf are targeted therapies that shut down specific pathways used by cancer to grow. Mutated copies of the BRAF V600 protein are found in about half of all melanomas.